BML-259

Overview

BML-259 is a potent cyclin-dependent kinase 5 ( Cdk5 ) inhibitor, with IC 50 s of 64 and 98 nM for Cdk5 and Cdk2 , respectively.

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-108348
• CAS No.: 267654-00-2
• Molecular Formula: C14H16N2OS
• Molecular Weight: 260.35
• Purity: 99.12%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source